Advertisement

Pharmaceutisch weekblad

, Volume 3, Issue 1, pp 1549–1559 | Cite as

Vascular aspects of calcium antagonists

  • P. A. Van Zwieten
  • J. C. A. Van Meel
  • P. B. M. W. M. Timmermans
Review Articles

Abstract

Calcium antagonistic drugs have been recognized as useful antiarrhythmic agents for approximately a decade. More recently, however, their vascular effects have been shown to be of potential therapeutic and pharmacological interest, especially in the treatment of angina pectoris involving coronary arterial spasm and possibly also of hypertension. The present survey is dealing with the circulatory changes of the calcium antagonists, describing the influence of the drugs on the systemic and coronary circulation, as well as on special vascular beds like the renal and cerebral circulatory tracts. The influence of the calcium antagonistic agents on vascular smooth muscle at a cellular level is the main subject of the present article. The calcium antagonists inhibit the influx of calcium ions into the cell. Accordingly, they prevent the vasoconstriction, induced by the stimulation of vascularα2-adrenoceptors. However, the calcium antagonists do not blockα2-adrenoceptors as such, but they prevent the stimulation of the contractile proteins. This type of interaction has been demonstrated in various animal species for a variety of calcium antagonists on the one hand and for several selective or non-selectiveα2-adrenoceptor stimulants on the other hand. The vasodilator effect of calcium antagonists may be explained by the selective inhibition of the vasoconstriction, induced by the stimulation ofα2-adrenoceptors by endogenous (nor)adrenaline.

Keywords

Nifedipine Calcium Antagonist Pressor Response Nimodipine Methoxamine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abboud, F.M. (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.Google Scholar
  2. Bevan, J.A. (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.Google Scholar
  3. Bing, R.J., M. Ohashi andT. Yamakawa (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.Google Scholar
  4. Bohr, D.F. (1963)Science 139, 579–599.CrossRefGoogle Scholar
  5. Cambridge, D., M.J. Davey andR. Massingham (1977)Brit. J. Pharmacol. 59, 514P-515P.Google Scholar
  6. Deth, R., andC. Van Breemen (1974)Pflugers Arch. Ges. Physiol. 348, 13–22.CrossRefGoogle Scholar
  7. Doxey, J.C., C.F.C. Smith andJ.M. Walker (1977)Brit. J. Pharmacol. 60, 91–96.CrossRefGoogle Scholar
  8. Fleckenstein, A. (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.Google Scholar
  9. Fleckenstein, A., K. Nakayama, G. Fleckenstein-Grün andY.K. Byon (1975) In:Calcium Transport in Contraction and Secretion (Carafoli, E.,et al., Eds.). North-Holland Publishing Company, Amsterdam-Oxford, 555–566.Google Scholar
  10. Godfraind, T., andA. Kaba (1972)Arch. Intern. Pharmocodyn. (Suppl.) 196, 35–36.Google Scholar
  11. Godfraind, T., andR.C. Miller (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.Google Scholar
  12. Goodman, F.R., andG.B. Weiss (1971)J. Pharmacol. Exp. Therap. 17, 415–425.Google Scholar
  13. Grün, G., andA. Fleckenstein (1972)Arzneimittel-Forsch. 22, 334–344.Google Scholar
  14. Hester, R.K., andO. Carrier (1977)Factors influencing vascular reactivity. Igaku-Shoin, Tokyo-New York, 96–105.Google Scholar
  15. Kahan, A., S. Weber, B. Amor, L. Saporta, M. Hodara, M. DeGeorges (1981) VIIIth Int. Congress of Pharmacology, 1981, Abstr. nr. 1911, Tokyo, Japan.Google Scholar
  16. Koch-Weser, J. (1976)New Engl. J. Med. 295, 320–323.CrossRefPubMedGoogle Scholar
  17. Kukovetz, W.R., G. Pöch andA. Wurm (1976) In:Ionic actions on vascular smooth muscle (Etz, E., Ed.). Springer-Verlag, Berlin, 124–131.CrossRefGoogle Scholar
  18. Lederballe Pedersen, O., N.J. Christensen andK.D. Rämsch (1980)J. Cardiov. Pharmacol. 2, 357–366.CrossRefGoogle Scholar
  19. Lefèvre-Borg, F., andI. Cavero (1982)Brit. J. Pharmacol., in press.Google Scholar
  20. Meinertz, T., andH. Scholz (1969)Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmacol. 264, 281–282.CrossRefGoogle Scholar
  21. Meel, J.C.A. Van, A. De Jonge, B. Wilffert, H.O. Kalkman, P.B.M.W.M. Timmermans andP.A. Van Zwieten (1981a)Eur. J. Pharmacol. 69, 205–208.CrossRefPubMedGoogle Scholar
  22. Meel, J.C.A. Van, A. De Jonge, H.O. Kalkman, B. Wilffert, P.B.M.W.M. Timmermans andP.A. Van Zwieten (1981b)Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmacol. 316, 288–293.CrossRefPubMedGoogle Scholar
  23. Meel, J.C.A. Van, B. Wilffert, K. De Zoeten, P.B.M.W.M. Timmermans andP.A. Van Zwieten (1982)Arch. Intern. Pharmacodyn., in press.Google Scholar
  24. Mostbeck, A., K. Partsch andL. Perschl (1975)First International Nifedipine ‘Adalat’ Symposium, Tokyo (Hashimoto et al., Eds.). University of Tokyo Press, Tokyo, 136.Google Scholar
  25. Olivari, M.T., C. Bartorelli, A. Polese, C. Fiorentini, P. Moruzzi andM.D. Guazzi (1979)Circulation 59, 1056–1062.CrossRefPubMedGoogle Scholar
  26. Schädler, M. (1967)Pflügers Arch. Ges. Physiol. 296, 70–90.CrossRefGoogle Scholar
  27. Singh, B.N., G. Eilrodt andC.T. Peter (1978)Drugs 15, 169–197.CrossRefPubMedGoogle Scholar
  28. Sitrin, M.D., andD.F. Bohr (1971)Am. J. Physiol. 220, 1124–1128.PubMedGoogle Scholar
  29. Stoclet, J.C., andC. Lugnier (1978) In:Mechanisms of Vasodilatation (Vanhoutte, P.M., andI. Lensen, Eds.). S. Karger AG, Basel, 152–157.CrossRefGoogle Scholar
  30. Takenaka, T., T. Usada, T. Nomura, H. Maeno andT. Sato (1976)Arzneimittel-Forsch. 26, 2172–2178.Google Scholar
  31. Tanaka, K., F. Gotoh, F. Muramatsu, Y. Fukuuchi, T. Amano, H. Okayasu andN. Suzuki (1980)Arzneimittel-Forsch. 30, 1494–1497.Google Scholar
  32. Thuillez, C., andJ.F. Giudicelli (1981)Therapie 36, 107–121.PubMedGoogle Scholar
  33. Towart, R. (1981)Circulation Res. 48, 650–657.CrossRefPubMedGoogle Scholar
  34. Vatner, S.F., T.H. Hintze andP. Macho (1981) Symposium on calcium blocking agents. VIIIth Int. Congress of Pharmacology, 1981, Tokyo, Japan.Google Scholar
  35. Weitzell, R., T. Tanaka andK. Starke (1979)Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmacol. 308, 127–136.CrossRefPubMedGoogle Scholar
  36. Zsotér, T.T. (1980)Am. Heart J. 99, 805–810.CrossRefPubMedGoogle Scholar
  37. Zwieten, P.A. Van, andP.B.M.W.M. Timmermans (1980)Pharm. Weekbl. Sci. Ed. 2, 161–171.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1981

Authors and Affiliations

  • P. A. Van Zwieten
    • 1
  • J. C. A. Van Meel
    • 1
  • P. B. M. W. M. Timmermans
    • 1
  1. 1.Department of Pharmacy, Division of PharmacotherapyUniversity of AmsterdamTV AmsterdamThe Netherlands

Personalised recommendations